Let’s start up with the current stock price of Syros Pharmaceuticals Inc. (SYRS), which is $9.10 to be very precise. The Stock rose vividly during the last session to $9.92 after opening rate of $8.69 while the lowest price it went was recorded $8.385 before closing at $7.76.
Recently in News on December 5, 2020, Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML. 61% Composite CR Rate in RARA-Positive Newly Diagnosed Unfit AML Patients, with Median Overall Survival of 18 Months Among Responders . You can read further details here
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Syros Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $14.69 on 08/21/20, with the lowest value was $4.26 for the same time period, recorded on 03/17/20.
Syros Pharmaceuticals Inc. (SYRS) full year performance was 97.83%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Syros Pharmaceuticals Inc. shares are logging -38.05% during the 52-week period from high price, and 113.62% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $4.26 and $14.69.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2137023 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Syros Pharmaceuticals Inc. (SYRS) recorded performance in the market was 31.69%, having the revenues showcasing 1.79% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 410.41M, as it employees total of 83 workers.
The Analysts eye on Syros Pharmaceuticals Inc. (SYRS)
During the last month, 7 analysts gave the Syros Pharmaceuticals Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 9.83, with a change in the price was noted -2.63. In a similar fashion, Syros Pharmaceuticals Inc. posted a movement of -22.42% for the period of last 100 days, recording 444,510 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for SYRS is recording 0.44 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.44.
Technical rundown of Syros Pharmaceuticals Inc. (SYRS)
Raw Stochastic average of Syros Pharmaceuticals Inc. in the period of last 50 days is set at 71.24%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 68.03%. In the last 20 days, the company’s Stochastic %K was 29.99% and its Stochastic %D was recorded 18.00%.
Considering, the past performance of Syros Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 31.69%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -4.61%, alongside a boost of 97.83% for the period of the last 12 months. The shares increased approximately by 11.66% in the 7-day charts and went down by 12.21% in the period of the last 30 days. Common stock shares were driven by 1.79% during last recorded quarter.